CR20110670A - Nuevos conjugados, su preparación y su aplicación terapéutica - Google Patents
Nuevos conjugados, su preparación y su aplicación terapéuticaInfo
- Publication number
- CR20110670A CR20110670A CR20110670A CR20110670A CR20110670A CR 20110670 A CR20110670 A CR 20110670A CR 20110670 A CR20110670 A CR 20110670A CR 20110670 A CR20110670 A CR 20110670A CR 20110670 A CR20110670 A CR 20110670A
- Authority
- CR
- Costa Rica
- Prior art keywords
- preparation
- therapeutic application
- new conjugates
- objects
- illumination
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000005286 illumination Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un método y aparato para la autoiluminación de varios objetos diseñados para usarse en actividades relacionadas con deportes, entretenimiento, seguridad, y emergencia. Se provoca la autoiluminación de los objetos por quimioluminiscencia para facilitar el uso de los objetos durante horas sin luz diurna o en áreas que de otra manera están rodeados por oscuridad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0903170A FR2947269B1 (fr) | 2009-06-29 | 2009-06-29 | Nouveaux composes anticancereux |
FR0905651A FR2947271B1 (fr) | 2009-06-29 | 2009-11-25 | Nouveaux composes anticancereux |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110670A true CR20110670A (es) | 2012-02-09 |
Family
ID=41611078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110670A CR20110670A (es) | 2009-06-29 | 2011-12-13 | Nuevos conjugados, su preparación y su aplicación terapéutica |
Country Status (30)
Country | Link |
---|---|
US (1) | US8952147B2 (es) |
EP (1) | EP2448929A1 (es) |
JP (1) | JP5746692B2 (es) |
KR (1) | KR101770584B1 (es) |
CN (1) | CN102482238B (es) |
AR (1) | AR078131A1 (es) |
BR (1) | BRPI1015131A2 (es) |
CA (1) | CA2766762C (es) |
CL (1) | CL2011003229A1 (es) |
CO (1) | CO6430462A2 (es) |
CR (1) | CR20110670A (es) |
DO (1) | DOP2011000376A (es) |
EA (1) | EA024627B1 (es) |
EC (1) | ECSP11011553A (es) |
FR (2) | FR2947269B1 (es) |
HN (1) | HN2011003414A (es) |
IL (1) | IL217208A (es) |
MA (1) | MA33465B1 (es) |
MX (1) | MX2011013764A (es) |
MY (1) | MY156684A (es) |
NI (1) | NI201100219A (es) |
NZ (1) | NZ597136A (es) |
PE (1) | PE20121031A1 (es) |
SG (2) | SG177419A1 (es) |
SV (1) | SV2011004086A (es) |
TN (1) | TN2011000636A1 (es) |
TW (1) | TW201110986A (es) |
UY (1) | UY32745A (es) |
WO (1) | WO2011001052A1 (es) |
ZA (1) | ZA201109537B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
MX349210B (es) | 2009-06-03 | 2017-07-18 | Immunogen Inc | Métodos de conjugación. |
AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
KR20220009505A (ko) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
AR087760A1 (es) | 2011-09-02 | 2014-04-16 | Incyte Corp | Heterociclilaminas como inhibidores de pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US10035817B2 (en) | 2012-10-04 | 2018-07-31 | Immunogen, Inc. | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
AU2014286990A1 (en) | 2013-07-11 | 2016-02-11 | Novartis Ag | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
KR102632830B1 (ko) * | 2014-09-03 | 2024-02-02 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
PT3262046T (pt) | 2015-02-27 | 2020-12-24 | Incyte Corp | Sais de inibidor de pi3k e processos para a sua preparação |
EP3069734A1 (en) | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
JP6412906B2 (ja) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
WO2017136769A1 (en) * | 2016-02-04 | 2017-08-10 | Eisai R&D Management Co., Ltd. | Peptide drug conjugates |
WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
AR111781A1 (es) * | 2017-05-10 | 2019-08-21 | Sanofi Sa | Ligadores peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico |
CA3072399A1 (en) | 2017-08-09 | 2019-02-14 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
AU2018389100A1 (en) * | 2017-12-22 | 2020-07-09 | Cornell University | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
WO2021067460A1 (en) | 2019-09-30 | 2021-04-08 | The Regents Of The University Ofmichigan | Biocatalytic synthesis of cryptophycin anticancer agents |
EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023057564A1 (en) | 2021-10-07 | 2023-04-13 | Sanofi | IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2719170A (en) | 1954-07-28 | 1955-09-27 | Du Pont | Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters |
US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
AU645745B2 (en) | 1988-12-22 | 1994-01-27 | Xoma Corporation | Hindered linking agents and methods |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2056039A1 (en) | 1991-01-22 | 1992-07-23 | Philip L. Fuchs | Carbacyclin analogs |
EP0830136B1 (en) | 1995-03-07 | 2004-10-20 | University Of Hawaii | New cryptophycins from synthesis |
EP0934065B1 (en) * | 1996-08-30 | 2006-06-07 | University Of Hawaii | Novel cryptophycin derivatives as anti-neoplastic agents |
WO2000023429A2 (en) | 1998-10-16 | 2000-04-27 | Eli Lilly And Company | Stereoselective process for producing cryptophycins |
WO2000034252A2 (en) | 1998-12-07 | 2000-06-15 | Eli Lilly And Company | Process for the preparation of cryptophycin derivatives |
WO2003043583A2 (en) * | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
US6913748B2 (en) | 2002-08-16 | 2005-07-05 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
BRPI0410748B8 (pt) | 2003-05-20 | 2021-05-25 | Immunogen Inc | compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular |
JP2007503202A (ja) | 2003-07-21 | 2007-02-22 | イミュノジェン・インコーポレーテッド | Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
SV2006002258A (es) | 2004-10-08 | 2006-09-19 | Wyeth Corp | Inmunoterapia de trastornos autoinmunes |
EP1669358A1 (en) | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
EP1819359B1 (en) * | 2004-12-09 | 2015-03-18 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods of their production and their use |
CA3005835C (en) | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
JP2008536485A (ja) * | 2005-03-07 | 2008-09-11 | アーケミックス コーポレイション | Psmaに対する安定化したアプタマーおよび前立腺癌治療薬としてのそれらの使用 |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
ES2374964T3 (es) | 2006-01-25 | 2012-02-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina. |
EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
US8212083B2 (en) | 2006-04-27 | 2012-07-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
JP5622390B2 (ja) | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
ES2435779T3 (es) | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
MY159553A (en) | 2008-04-11 | 2017-01-13 | Seattle Genetics Inc | Detection and treatment of pancreatic, ovarian and other cancers |
AU2009243009B2 (en) | 2008-04-30 | 2014-09-11 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
PL2281006T3 (pl) | 2008-04-30 | 2018-01-31 | Immunogen Inc | Środki łączące i ich zastosowania |
WO2010014812A2 (en) | 2008-07-30 | 2010-02-04 | The Research Foundation Of State University Of New York | Peptide compositions and methods of use |
-
2009
- 2009-06-29 FR FR0903170A patent/FR2947269B1/fr not_active Expired - Fee Related
- 2009-11-25 FR FR0905651A patent/FR2947271B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-20 CN CN201080038575.2A patent/CN102482238B/zh not_active Expired - Fee Related
- 2010-05-20 MA MA34580A patent/MA33465B1/fr unknown
- 2010-05-20 EP EP10728799A patent/EP2448929A1/fr not_active Withdrawn
- 2010-05-20 KR KR1020117031276A patent/KR101770584B1/ko active IP Right Grant
- 2010-05-20 CA CA2766762A patent/CA2766762C/fr not_active Expired - Fee Related
- 2010-05-20 NZ NZ597136A patent/NZ597136A/en not_active IP Right Cessation
- 2010-05-20 PE PE2011002178A patent/PE20121031A1/es not_active Application Discontinuation
- 2010-05-20 SG SG2011097193A patent/SG177419A1/en unknown
- 2010-05-20 BR BRPI1015131-1A patent/BRPI1015131A2/pt not_active Application Discontinuation
- 2010-05-20 MX MX2011013764A patent/MX2011013764A/es active IP Right Grant
- 2010-05-20 EA EA201270096A patent/EA024627B1/ru not_active IP Right Cessation
- 2010-05-20 MY MYPI2011006289A patent/MY156684A/en unknown
- 2010-05-20 JP JP2012518108A patent/JP5746692B2/ja not_active Expired - Fee Related
- 2010-05-20 SG SG10201607595WA patent/SG10201607595WA/en unknown
- 2010-05-20 WO PCT/FR2010/050986 patent/WO2011001052A1/fr active Application Filing
- 2010-06-28 TW TW099121094A patent/TW201110986A/zh unknown
- 2010-06-28 AR ARP100102290A patent/AR078131A1/es unknown
- 2010-06-29 UY UY0001032745A patent/UY32745A/es not_active Application Discontinuation
-
2011
- 2011-12-05 DO DO2011000376A patent/DOP2011000376A/es unknown
- 2011-12-12 TN TNP2011000636A patent/TN2011000636A1/fr unknown
- 2011-12-13 CR CR20110670A patent/CR20110670A/es unknown
- 2011-12-15 SV SV2011004086A patent/SV2011004086A/es unknown
- 2011-12-19 NI NI201100219A patent/NI201100219A/es unknown
- 2011-12-20 CL CL2011003229A patent/CL2011003229A1/es unknown
- 2011-12-20 US US13/331,259 patent/US8952147B2/en not_active Expired - Fee Related
- 2011-12-23 ZA ZA2011/09537A patent/ZA201109537B/en unknown
- 2011-12-26 IL IL217208A patent/IL217208A/en not_active IP Right Cessation
- 2011-12-26 EC EC2011011553A patent/ECSP11011553A/es unknown
- 2011-12-28 HN HN2011003414A patent/HN2011003414A/es unknown
- 2011-12-29 CO CO11180696A patent/CO6430462A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110670A (es) | Nuevos conjugados, su preparación y su aplicación terapéutica | |
CR20150586A (es) | Compuestos triciclicos que contienen nitrogeno como agentes antibactercianos | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
CL2008000825A1 (es) | Compuestos heterociclicos derivados de quinolincarboxamidas utiles como antagonistas de p2x7; su metodo de preparacion; la composicion farmaceutica que lo contiene; el emtodo de preparacion de la composicion; y el uso de los mismos para preparar medicamentos utiles en artritis reumatoide. | |
CL2014002096A1 (es) | Compuestos heterocíclicos que comprenden un sistema enediino; conjugados de los mismos; composiciones que los comprenden; y uso para tratar el cáncer | |
CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
CL2013001783A1 (es) | Analogos de glucagon que presentan actividad potente en receptor de gip; dimero o multidimero; conjugado; composicion farmaceutica que los comprende; y sus usos en tratar diabetes u obesidad. | |
CL2008001446A1 (es) | Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico. | |
UY34418A (es) | Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
PE20211094A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
ECSP10010344A (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
CL2013001754A1 (es) | Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias. | |
ECSP11011347A (es) | Nicotinamida sustituida como moduladores KCNQ2/3 | |
CR20110497A (es) | Nuevos anticuerpos anti-alfa5beta1 y sus usos | |
CL2008001835A1 (es) | Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende. | |
ECSP12012301A (es) | Colorantes de perileno enlazados a polímero y composiciones que los contienen | |
CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
CR10481A (es) | Equipo, sistemas y metodos para confirmar el uso de un dispositivo oral | |
CO7020909A2 (es) | Compuesto tricíclicos, composiciones que los comprenden y uso de los mismos | |
CO6640301A2 (es) | Compuestos ologo-benzamida y su uso | |
CL2012000508A1 (es) | Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas. | |
CO6470793A2 (es) | Antagonistas ccr3 arilsulfonamida | |
DOP2010000361A (es) | Dronedarona para la prevencion de la cardioversion |